265 related articles for article (PubMed ID: 37436507)
1. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus.
Cheng S; Hu G; Jin Z; Wang Z; Xue H
Eur Radiol; 2023 Dec; 33(12):8715-8726. PubMed ID: 37436507
[TBL] [Abstract][Full Text] [Related]
2. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
3. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
Zhang L; Sun JH; Hou ZH; Zhong BY; Yang MJ; Zhou GH; Wang WS; Huang P; Zhang S; Li Z; Zhu XL; Yan ZP; Ni CF
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):63-72. PubMed ID: 32965582
[TBL] [Abstract][Full Text] [Related]
4. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
Lyu T; Yao H; Wang J; Song L; Tong X; Zou Y
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101819. PubMed ID: 34619365
[TBL] [Abstract][Full Text] [Related]
5. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection.
Liu F; Guo X; Dong W; Zhang W; Wei S; Zhang S; Zhu X; Zhou W; Zhang J; Liu H
Int J Biol Sci; 2020; 16(16):3210-3220. PubMed ID: 33162826
[No Abstract] [Full Text] [Related]
8. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
9. Machine Learning-Based Development of Nomogram for Hepatocellular Carcinoma to Predict Acute Liver Function Deterioration After Drug-Eluting Beads Transarterial Chemoembolization.
Li J; Zhang Y; Ye H; Hu L; Li X; Li Y; Yu P; Wu B; Lv P; Li Z
Acad Radiol; 2023 Sep; 30 Suppl 1():S40-S52. PubMed ID: 37316369
[TBL] [Abstract][Full Text] [Related]
10. Radiomics nomogram for the prediction of microvascular invasion of HCC and patients' benefit from postoperative adjuvant TACE: a multi-center study.
Zhang K; Zhang L; Li WC; Xie SS; Cui YZ; Lin LY; Shen ZW; Zhang HM; Xia S; Ye ZX; He K; Shen W
Eur Radiol; 2023 Dec; 33(12):8936-8947. PubMed ID: 37368104
[TBL] [Abstract][Full Text] [Related]
11. Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads.
Cheng S; Yu X; Liu S; Jin Z; Xue H; Wang Z; Xie P
Cancer Manag Res; 2021; 13():9367-9377. PubMed ID: 34992462
[TBL] [Abstract][Full Text] [Related]
12. Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT.
Ma X; Wei J; Gu D; Zhu Y; Feng B; Liang M; Wang S; Zhao X; Tian J
Eur Radiol; 2019 Jul; 29(7):3595-3605. PubMed ID: 30770969
[TBL] [Abstract][Full Text] [Related]
13. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.
Li L; Kan X; Zhao Y; Liang B; Ye T; Yang L; Zheng C
Int J Med Sci; 2021; 18(11):2276-2284. PubMed ID: 33967603
[No Abstract] [Full Text] [Related]
14. Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study.
Zhao GS; Liu S; Liu Y; Li C; Wang RY; Bian J; Zhang YW; Zhou J; Lin YJ; Wu J
Expert Rev Gastroenterol Hepatol; 2022 Jul; 16(7):673-680. PubMed ID: 35709813
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
16. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
Chen J; Lai L; Luo J; Wang H; Li M; Huang M
BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104
[TBL] [Abstract][Full Text] [Related]
17. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
[TBL] [Abstract][Full Text] [Related]
18. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection.
Fu YP; Yi Y; Huang JL; Jing CY; Sun J; Ni XC; Lu ZF; Cao Y; Zhou J; Fan J; Qiu SJ
Oncologist; 2017 May; 22(5):561-569. PubMed ID: 28438885
[TBL] [Abstract][Full Text] [Related]
20. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
Liu K; Zheng X; Lu D; Tan Y; Hou C; Dai J; Shi W; Jiang B; Yao Y; Lu Y; Cao Q; Chen R; Zhang W; Xie J; Chen L; Jiang M; Zhang Z; Liu L; Liu J; Li J; Lv W; Wu X
Radiol Med; 2024 Jan; 129(1):14-28. PubMed ID: 37863847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]